Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lymphoma Study Association
Age
80–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification). DLBCL with some small cell infiltration in bone marrow or lymph node may be included.
Aged over 80 years.
Ann Arbor stage I bulky, II, III or IV
Age-adjusted International Prognostic Index equal to 0, 1, 2 and 3.
Patient non previously treated.
ECOG performance status ≤ 2.
With a minimum life expectancy of 3 months.
Negative HIV, HBV and HCV serologies test ≤ 4 weeks (except after vaccination).
Having previously signed a written informed consent
You may not be if
Any other histological type of lymphoma.
Any history of treated or non-treated indolent lymphoma.
Central nervous system or meningeal involvement by lymphoma.
Contra-indication to any drug contained in the chemotherapy regimens.
Any serious active disease (according to the investigator's decision).
Poor renal function (creatinin level\>150µmol/l), poor hepatic function (total bilirubin level\>30mmol/l, transaminases\>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration.
Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
Adult patient under tutelage.
Clareo Health | Mini-CHOP and Rituximab in Patients Aged Over 80 Years
